Results 41 to 50 of about 6,010 (246)

HIV LTR-Driven Antisense RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency

Frontiers in Microbiology, 2018
Latently infected T lymphocytes are an important barrier toward eliminating a persistent HIV infection. Here we describe an HIV-based recombinant fluorescent-lentivirus referred to as “rfl-HIV” that enables to analyze sense and antisense transcription by
Mie Kobayashi-Ishihara, Mie Kobayashi-Ishihara, Kazutaka Terahara, Javier P. Martinez, Makoto Yamagishi, Ryutaro Iwabuchi, Ryutaro Iwabuchi, Christian Brander, Christian Brander, Christian Brander, Manabu Ato, Manabu Ato, Toshiki Watanabe, Andreas Meyerhans, Andreas Meyerhans, Yasuko Tsunetsugu-Yokota, Yasuko Tsunetsugu-Yokota, Yasuko Tsunetsugu-Yokota   +17 more
doaj   +1 more source

Pathways towards human immunodeficiency virus elimination

EBioMedicine, 2020
Antiretroviral therapy (ART) suppresses human immunodeficiency virus (HIV) infection. Research seeking to transform viral suppression into elimination has generated novel immune, chemical and molecular antiviral agents.
Prasanta K. Dash, Bhavesh D. Kevadiya, Hang Su, Mary G. Banoub, Howard E. Gendelman   +4 more
doaj   +1 more source

The role of latency reversal agents in the cure of HIV: A review of current data [PDF]

Immunology Letters, 2018
The definitive cure for human immunodeficiency virus type-1 (HIV) infection is represented by the eradication of the virus from the patient's body. To reach this result, cells that are infected but do not produce the virus must become recognizable to be killed by the immune system.
Bashiri, Kiandokht, Rezaei, Nima, Nasi, Milena, Cossarizza, Andrea   +3 more
openaire   +3 more sources

Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo [PDF]

, 2021
An ability to activate latent HIV-1 expression could benefit many HIV cure strategies, but the first generation of latency reversing agents (LRAs) has proven disappointing. We evaluated AKT/mTOR activators as a potential new class of LRAs.
Roan, Nadia R, Ott, Melanie, Deeks, Steven G, Hogan, Louise E, Gramatica, Andrea, Connors, Mark, Okoye, Afam A, Rosenthal, Danielle, Herzig, Eytan, Schwarzer, Roland, Besnard, Emilie, Picker, Louis J, Hsiao, Feng, Verdin, Eric, Montano, Mauricio, Nekorchuk, Michael, Packard, Thomas A, Lifson, Jeffrey D, Kiernan, Bernard, Estes, Jacob D, Varco-Merth, Benjamin, Grimmett, Zachary W, Greene, Warner C, Brantley, William, Sperber, Hannah S, Krogan, Nevan J, Hull, Philip A, Migueles, Stephen A, Henrich, Timothy J, Pillai, Satish K, Johnson, Jeffrey R, Snape, Michael   +31 more
core   +1 more source

Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent

Journal of Antimicrobial Chemotherapy, 2020
AbstractObjectivesTo develop a population pharmacokinetic model for romidepsin given as an HIV latency reversing agent (LRA) and to explore the relationship between romidepsin exposure and its in vivo effects on viral gene expression and antiviral immunity.MethodsA population pharmacokinetic analysis was performed in 15 HIV-1-infected patients who ...
José Moltó, Miriam Rosás-Umbert, Cristina Miranda, Christian Manzardo, Maria C Puertas, Marta Ruiz-Riol, Miriam López, Jose M Miró, Javier Martinez-Picado, Bonaventura Clotet, Christian Brander, Beatriz Mothe, Marta Valle   +12 more
openaire   +3 more sources

PARP1 Might Substitute HSF1 to Reactivate Latent HIV-1 by Binding to Heat Shock Element

Cells, 2022
At present, the barrier to HIV-1 functional cure is the persistence of HIV-1 reservoirs. The “shock (reversing latency) and kill (antiretroviral therapy)” strategy sheds light on reducing or eliminating the latent reservoir of HIV-1. However, the current
Xinfeng Xu, Yingtong Lin, Xiaoyun Zeng, Chan Yang, Siqin Duan, Liqiong Ding, Wanzhen Lu, Jian Lin, Xiaoyan Pan, Xiancai Ma, Shuwen Liu   +10 more
doaj   +1 more source

Engineering CAR T Cells to Target the HIV Reservoir

Frontiers in Cellular and Infection Microbiology, 2020
The HIV reservoir remains to be a difficult barrier to overcome in order to achieve a therapeutic cure for HIV. Several strategies have been developed to purge the reservoir, including the “kick and kill” approach, which is based on the notion that ...
Wenli Mu, Mayra A. Carrillo, Scott G. Kitchen   +2 more
doaj   +1 more source

Lnc(ing)RNAs to the “shock and kill” strategy for HIV-1 cure

Molecular Therapy: Nucleic Acids, 2021
The advent of antiretroviral therapy almost 25 years ago has transformed HIV-1 infection into a manageable chronic condition, albeit still incurable. The inability of the treatment regimen to eliminate latently infected cells that harbor the virus in an ...
Saikat Boliar, David G. Russell
doaj   +1 more source

Novel Triazolopyridine-Based BRD4 Inhibitors as Potent HIV‑1 Latency Reversing Agents

, 2023
Bromodomain-containing protein 4 (BRD4) inhibitors have been proven to be a promising option for anti-HIV-1 latency therapeutics. We herein describe the design, synthesis, and anti-HIV-1 latency bioevaluation of triazolopyridine derivatives as BRD4 ...
Zhi-Yu Li (7008698), Xun Li (182737), Ren-Rong Tian (2649721), Wei Hu (6560), Meng-Di Ma (17634972), Hai-Peng Yu (17634975), Tai-Fu Xiao (17634978), Liu-Meng Yang (489446), Xu-Sheng Huang (390011), Rong-Hua Luo (489444), Yong-Tang Zheng (311182), Yan-Kai Wang (17634969), Hao Sun (14095), Zhong Li (324520)   +13 more
core   +1 more source

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen [PDF]

PLOS ONE, 2020
Although current antiretroviral therapies (ART) are successful in controlling HIV-1 infection, a stable viral reservoir reactivates when ART is discontinued. Consequently, there is a major research effort to develop approaches to disrupt the latent viral reservoir and enhance the immune system’s ability to clear HIV-1.
Hongbing Liu, Pei-Wen Hu, Julien Dubrulle, Fabio Stossi, Bryan C. Nikolai, Michael A. Mancini, Andrew P. Rice   +6 more
openaire   +4 more sources